Latest OBT Stories
OXFORD, England, April 29, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP(R) discovery platform. Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following...
OXFORD, England and FLORENCE, Italy, October 29, 2012 /PRNewswire/ -- Menarini and Oxford BioTherapeutics (OBT) today announce a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer. The agreement covers five of OBT's antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target. The deal brings together OBT's discovery expertise with...
OXFORD, England, May 2, 2012 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he will lead the company's newly created clinical development operations based in Basel, Switzerland. The establishment of a dedicated development operation represents a key milestone in OBT's global expansion as it progresses its most advanced therapeutic antibody and antibody...
OXFORD, England, January 11, 2012 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announces that it has appointed C. Glenn Begley as a senior clinical advisor and non-executive director. Dr Begley, who was the Vice President and Global Head of Hematology and Oncology Research at Amgen, will take on a key role in helping shape and execute OBT's clinical and corporate strategy as it advances its pipeline of oncology antibody-based drugs into clinical development. C....
SEATTLE and COPENHAGEN, Denmark and OXFORD, England, Sept. 7, 2011 /PRNewswire/ -- CMC Biologics and Oxford BioTherapeutics (OBT) today announced that they have entered into a non-exclusive license agreement providing OBT with access to CMC Biologics' CHEF1® expression system. The agreement, financial terms of which have not been disclosed, covers the research, development, and commercial use of the system by OBT. CMC Biologics' CHEF1 cell line development platform promotes high level...
OXFORD, England, January 25, 2011 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announces that sanofi-aventis has acquired an exclusive world-wide license to one of OBT's internal preclinical antibody programs. sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. ADC products comprise toxins...
OXFORD, England, December 9 /PRNewswire/ -- - Appointment Follows Recent Recruitment of Senior Antibody Industry Leaders and Highlights OBT's Growth Into a Leading Oncology-Focused Therapeutic Antibody Company Oxford BioTherapeutics (OBT) has today announced the appointment of Dr Michael Moore as non-executive Chairman. Dr Moore brings considerable expertise and experience to OBT at an exciting phase in the Company's development, as it capitalises on partnerships with GSK,...
OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will...
